SELB
NASDAQSelecta Biosciences Inc.
Latest news
25 items- SECSEC Form DEFA14A filed by Selecta Biosciences Inc.DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSEC Form DEF 14A filed by Selecta Biosciences Inc.DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- 13D/GSEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
- 13D/GSEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
- 13D/GSEC Form SC 13G filed by Selecta Biosciences Inc.SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)
- SECSEC Form PRE 14A filed by Selecta Biosciences Inc.PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSelecta Biosciences Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)8-K/A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSelecta Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSEC Form S-8 filed by Selecta Biosciences Inc.S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECSelecta Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for AutoimmunityTopline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D
- PRCartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia GravisDurable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap
- INSIDERSinger Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERDavis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERJewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERBrunn Carsten was granted 4,654,100 shares, increasing direct ownership by 1,777% to 4,916,056 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERSallin Aymeric was granted 178,000 units of Common Stock (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERBarabe Timothy C was granted 178,000 shares, increasing direct ownership by 71% to 428,013 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERSpringer Timothy A was granted 178,000 shares, increasing direct ownership by 2% to 7,471,625 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERMiljkovic Milos was granted 548,200 units of Common Stock (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERDesilva Nishan M was granted 178,000 shares, increasing direct ownership by 2,543% to 185,000 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERCox Carrie Smith was granted 178,000 shares, increasing direct ownership by 84% to 390,881 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERZenner Patrick J was granted 178,000 shares, increasing direct ownership by 322% to 233,248 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERKalayoglu Murat was granted 178,000 units of Common Stock, increasing direct ownership by 69% to 435,739 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERKurtoglu Metin was granted 1,531,000 units of Common Stock (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
SELB FAQ
7 questionsWhat does Selecta Biosciences Inc. do?
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus...Where does SELB stock trade?
Selecta Biosciences Inc. (SELB) is listed on NASDAQ.What sector and industry is SELB in?
Selecta Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Selecta Biosciences Inc. go public?
Selecta Biosciences Inc. (SELB) completed its IPO in 2016.What are analysts saying about SELB?
Selecta Biosciences Inc. has had 4 recent analyst actions on file. The most recent action was from SVB Securities: Market Perform with a $100.00 price target on 2023-08-18.What companies are similar to SELB?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SELB side-by-side with any of them on Quantisnow.How can I track SELB on Quantisnow?
Quantisnow aggregates Selecta Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SELB to receive live email and push alerts on every new disclosure.